国药现代 (600420.SH) Latest Company News

Aug 28, 2026, 07:33 UTC
China National Medicines Corporation Ltd. received a drug registration certificate approved and issued by the National Medical Products Administration for Brexpiprazole tablets, an oral atypical antipsychotic drug for the treatment of adult schizophrenia, specification 2mg, registration classification as chemical drug category 4, deemed to have passed consistency evaluation.
Source:
- finance.sina.cn
Aug 18, 2026, 10:09 UTC
China Resources Double Crane received a drug registration certificate from the National Medical Products Administration for lidocaine hydrochloride gel, which is deemed to have passed consistency evaluation.
Source:
- finance.sina.cn
Aug 18, 2026, 09:19 UTC
Da An Gene announced it obtained a medical device registration certificate from China's National Medical Products Administration for its human parainfluenza virus nucleic acid detection kit (fluorescent PCR method), valid until August 16, 2031.
Source:
- finance.sina.cn
Aug 18, 2026, 09:16 UTC
China National Medicines' subsidiary Guoyao Rongsheng received approval from the National Medical Products Administration for its vitamin B12 injection, adding a new specification and passing the consistency evaluation for generic drugs.
Source:
- finance.sina.cn
Jul 30, 2026, 09:19 UTC
China National Medicines Corporation Ltd. announced that its subsidiary Sinopharm Zhijun Pingshan received regulatory approval to become the marketing authorization holder of lactulose oral solution.
Source:
- finance.sina.cn

600420.SH

China Resources Double Crane received a drug registration certificate from the National Medical Products Administration for lidocaine hydrochloride gel, which is deemed to have passed consistency evaluation.

Da An Gene announced it obtained a medical device registration certificate from China's National Medical Products Administration for its human parainfluenza virus nucleic acid detection kit (fluorescent PCR method), valid until August 16, 2031.

China National Medicines' subsidiary Guoyao Rongsheng received approval from the National Medical Products Administration for its vitamin B12 injection, adding a new specification and passing the consistency evaluation for generic drugs.

China National Medicines Corporation Ltd. announced that its subsidiary Sinopharm Zhijun Pingshan received regulatory approval to become the marketing authorization holder of lactulose oral solution.